Fasciocutaneous flaps in reconstruction of lower extremity: our experience

Abstract Objectives: The restoration of an intact covering is the primary surgical requisite following trauma of the lower extremity because deep healing can be no better than the surface covering. The present article is about our experience of lower limb reconstruction using fasciocutaneous flaps. Methods: 20 fasciocutaneous flaps in 15 males and 5 females were used for the wound / defect of lower limbs following trauma. Results: Fasciocutaneous flaps provided stable wound cover in 20 patients for leg wound/defect. 2 patients developed wound infection, 2 developed partial graft loss and 1 patient had partial flap necrosis. Conclusion: In the armamentarium of lower limb reconstruction fasciocutaneous flaps remains one of the useful methods of skin cover for leg wound/defects

Some 1,4-benzoxazino[2,3-<i>b</i>] phenoxazines derivatives as antibacterial, muscle relaxant and hypnotic agents

2254-22561,4-Benzoxazino[2,3-b]phenoxazines are synthesised by condensation of substituted anilines with halobenzoquinones followed by cyclisation. These compounds are screened for their antibacterial, muscle relaxant and hypnotic activities

Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.

PURPOSE: Contemporary treatment for metastatic hormone sensitive prostate cancer (mHSPC) includes androgen deprivation therapy (ADT) plus abiraterone or docetaxel. While these intensified regimens have improved efficacy, they are also associated with increased cost and toxicities. Not all men with mHSPC may be candidates for these intensified regimens, yet there are no clinical models or biomarkers used to optimize treatment selection. Herein, we hypothesized that longer time from prior definitive therapy (DT), either radical prostatectomy, definitive radiotherapy, or both, to onset of metastatic disease is associated with improved survival outcomes in men with newly diagnosed mHSPC. METHODS: This multicenter retrospective study included men initiating systemic therapy with ADT for new mHSPC. Kaplan-Meier and COX proportional hazard models assessed time to metastatic castration-resistant prostate cancer (mCRPC) and overall survival (OS) by receipt of prior DT. RESULTS: Of the 253 men with new mHSPC, 115 (45%) had received prior DT. In a multivariate analysis, increasing years from DT to the start of ADT was an independent predictor of time to mCRPC (per year: hazard ratio 0.91 95% confidence interval 0.84-0.99, P = 0.020) and improved OS (per year: hazard ratio 0.87, 95% confidence interval 0.74-0.99, P = 0.0025) in patients with new mHSPC, and may assist with risk stratification in these patients at time of mHSPC. CONCLUSION: Time from DT to start of ADT is an independent predictor of time to mCRPC and OS in men with new mHSPC, and may assist with risk stratification of these patients for systemic therapy selection